{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:17:53Z","timestamp":1747156673898,"version":"3.40.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.bulcan.2017.10.033","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T03:33:15Z","timestamp":1519183995000},"page":"275-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["L\u2019hypophysite auto-immune, complication des nouvelles immunoth\u00e9rapies anticanc\u00e9reuses"],"prefix":"10.1016","volume":"105","author":[{"given":"Arnaud","family":"Jannin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Merlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-1548","authenticated-orcid":false,"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2017.10.033_bib0120","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0125","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0130","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0135","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0140","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Fage","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0150","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/CCO.0000000000000293","article-title":"Endocrinological side effects of immune checkpoint inhibitors","volume":"28","author":"Torino","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0155","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 anti-body in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0160","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761034s000lbl.pdf. [Accessed on 16 May 2016]."},{"key":"10.1016\/j.bulcan.2017.10.033_bib0165","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0170","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/imt-2016-0147","article-title":"Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis","volume":"9","author":"Shang","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0180","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0185","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0190","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0195","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jjco\/hyx018","article-title":"Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab","volume":"47","author":"Kitajima","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0200","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ando.2014.07.245","article-title":"Polymorphisme de CTLA4\u00a0: un facteur pr\u00e9dictif de l\u2019auto-immunit\u00e9 endocrinienne sous ipilimumab\u00a0?","volume":"75","author":"Coppin","year":"2014","journal-title":"Annal Endocrinol"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0205","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash","volume":"12","author":"Nallapaneni","year":"2014","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy: immune checkpoint blockade and associated endocrinopathies","volume":"3","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 anti-body therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0220","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12032-010-9794-7","article-title":"Hyponatremia associated with ipilimumab-induced hypophysitis","volume":"29","author":"Barnard","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0225","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2017.10.033_bib0115","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117303867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117303867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T03:12:30Z","timestamp":1531105950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455117303867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0007455117303867"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.10.033","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u2019hypophysite auto-immune, complication des nouvelles immunoth\u00e9rapies anticanc\u00e9reuses","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}